Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights in animal models of neurotoxicity-induced neurodegeneration

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
The high prevalence of neurodegenerative diseases is an unintended consequence of the high longevity of the population, together with the lack of effective preventive and therapeutic options. There is great pressure on preclinical research, and both old and new models of neurodegenerative diseases are required to increase the pipeline of new drugs for clinical testing. We review here the main models of neurotoxicity-based animal models leading to central neurodegeneration. Our main focus was on studying how changes in neurotransmission and neuroinflammation, mainly in rodent models, contribute to harmful processes linked to neurodegeneration. The majority of the models currently in use mimic Parkinson's disease (PD) and Alzheimer's disease (AD), which are the most common neurodegenerative conditions in older adults. AD is the most common age-related dementia, whereas PD is the most common movement disorder with also cases of dementia. Several natural toxins and xenobiotic agents induce dopaminergic neurodegeneration and can reproduce neuropathological traits of PD. The literature analysis of MPTP, 6-OH-dopamine, and rotenone models suggested the latter as a useful model when specific doses of rotenone were administrated systemically to C57BL/6 mice. Cholinergic neurodegeneration is mainly modelled with the toxin scopolamine, which is a useful rodent model for the screening of protective drugs against cognitive decline and AD. Several agents have been used to model neuroinflammation-based neurodegeneration and dementia in AD, including lipopolysaccharide (LPS), streptozotocin, and monomeric C-reactive protein. The bacterial agent LPS makes a useful rodent model for testing anti-inflammatory therapies to halt the development and severity of AD. However, neurotoxin models might be more useful than genetic models for drug discovery in PD but that is not the case in AD where they cannot beat the new developments in transgenic mouse models. Overall, we should work using all available models, either in vivo, in vitro, or in silico, considering the seriousness of the moment and urgency of developing effective drugs., This research was funded by the Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB and PDC2021-121096) and by the European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resveratrol Activates Antioxidant Protective Mechanisms in Cellular Models of Alzheimer’s Disease Inflammation

  • Bartra Cabré, Clara
  • Yuan, Yi
  • Vuraić, Kristijan
  • Valdés-Quiroz, Haydeé
  • García-Baucells, Pau
  • Slevin, Mark
  • Pastorello, Ylenia
  • Suñol, Cristina
  • Sanfeliu, Coral
Resveratrol is a natural phenolic compound with known benefits against neurodegeneration. We analyzed in vitro the protective mechanisms of resveratrol against the proinflammatory monomeric C-reactive protein (mCRP). mCRP increases the risk of AD after stroke and we previously demonstrated that intracerebral mCRP induces AD-like dementia in mice. Here, we used BV2 microglia treated with mCRP for 24 h in the presence or absence of resveratrol. Cells and conditioned media were collected for analysis. Lipopolysaccharide (LPS) has also been implicated in AD progression and so LPS was used as a resveratrol-sensitive reference agent. mCRP at the concentration of 50 µg/mL activated the nitric oxide pathway and the NLRP3 inflammasome pathway. Furthermore, mCRP induced cyclooxygenase-2 and the release of proinflammatory cytokines. Resveratrol effectively inhibited these changes and increased the expression of the antioxidant enzyme genes Cat and Sod2. As central mechanisms of defense, resveratrol activated the hub genes Sirt1 and Nfe2l2 and inhibited the nuclear translocation of the signal transducer NF-ĸB. Proinflammatory changes induced by mCRP in primary mixed glial cultures were also protected by resveratrol. This work provides a mechanistic insight into the protective benefits of resveratrol in preventing the risk of AD induced by proinflammatory agents., This research was funded by Spanish MCIN/AEI/10.13039/501100011033, grant PID2019-106285RB-C22; MCIN/AEI/10.13039/501100011033 and EU Next Generation Funds/RTRP, grant PDC2021-121096-C22; AGAUR, Catalonia, grant 2021SGR357; the CERCA Programme/Generalitat de Catalunya; and Noi inhibitori ai proteinei C-reactive și blocanți de disociere pentru uz terapeutic în bolile cardiovasculare–CREDICARD, Contractului de finanțare nr. PCE 60/2021, cod proiect: PN-III-P4-ID-PCE-2020-1540., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics

  • Griñán-Ferré, Christian
  • Jarné-Ferrer, Júlia
  • Bellver-Sanchís, Aina
  • Codony, Sandra
  • Puigoriol-Illamola, Dolors
  • Sanfeliu, Coral
  • Oh, Yumin
  • Lee, Seulki
  • Vázquez, Santiago
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly, sEH inhibition could be related to other neuroprotective pathways described in AD., This work was supported by Spanish Ministerio de Ciencia e Innovación (PID2019-106285/AEI/10.13039/501100011033; PDC2021-121096/AEI/10.13039/501100011033; María de Maeztu Unit of Excellence to Institute of Neurosciences, University of Barcelona, MDM-2017-0729) and 2021SGR357 (AGAUR, Catalonia). ABS acknowledges a FI SDUR (2021 FI-B0812) fellowship to AGAUR Catalonia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Overcoming Pain Management: Unlocking the Power of Dual-Mechanism Compounds

  • Escriche, Celia
  • Sánchez, Javier
  • Pujol, Eugènia
  • Martínez-López, juan
  • Brea, José Manuel
  • Morisseau, Christophe
  • Pérez, Belén
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Loza, María Isabel
  • Vázquez, Santiago
Trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium: Harnessing the Power of New Drug Modalities, celebrado en Barcelona del 24 al 26 de abril de 2024, This work was funded by the Grants PID2020-118127RB-I00, to S.V., and PID2021-121096-C22, to C.S., funded by MICIU/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”, and the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. C.E.M. and J.S. thank the Spanish MICIU for PhD Grants (FPI program). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies

  • Jarne-Ferrer, Júlia
  • Sánchez, Javier
  • Codony, Sandra
  • Schneider, Marion
  • Müller, Christa E.
  • Sanfeliu, Coral
  • Franco, Rafael
  • Vazquez, Santiago
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a key pathological hallmark of Alzheimer's disease (AD). Recently, inhibiting soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic strategy for AD. sEH plays a pivotal role in neuroinflammation by hydrolyzing epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and neuroprotective properties, into pro-inflammatory dihydroepoxyeicosatrienoic acids (DHETs). Furthermore, the overexpression of the enzyme in the brains of AD patients and animal models of the disease highlights its relevance as a therapeutic target. Our previous studies, using the inhibitor UB-SCG-51 demonstrated that sEH inhibition regulates neuroinflammation and other mechanisms, such as the unfolded protein response pathway, while reducing autophagy, apoptosis, and neuronal death, thereby promoting neuroprotection. Building on these findings, we evaluated the arginine salt of the compound, designated UB-SCG-74, which offers improved oral absorption compared to that of UB-SCG-51 while retaining high permeability, potency, and selectivity. In experiments using 5XFAD mice, UB-SCG-74 treatment significantly improved cognition and synaptic plasticity, outperforming donepezil, a standard AD drug, and ibuprofen, an anti-inflammatory drug. Remarkably, these benefits persisted for 4 weeks after administration cessation, suggesting lasting therapeutic effects. Safety pharmacology studies showed no toxicity, supporting the advancement of UB-SCG-74 into preclinical regulatory evaluation. Our findings further indicate that sEH inhibition engages multiple neuroprotective pathways, potentially modifying both AD symptoms and disease progression, thus reinforcing its therapeutic potential., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and European Union NextGenerationEU/PRTR (PID2020-118127RB-I00/AEI/10.13039/501100011033 to S.V.; PDC2021-121096/AEI/10. 13039/501100011033 to M.P./C.S. PID2021-127693OB-I00 AEI/10.13039/501100011033 to C.G., PID2021-138079OB-I00 AEI/10.13039/501100011033 to M.P.), and Generalitat de Catalunya (2021 SGR 00357). J.S. was supported by the Research Personnel Training Program (FPI grant PRE2021-099446) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU), and Agencia Estatal de Investigación (AEI). C.G.F. and M.P. belong to María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona, CEX2021-001159-M, Ministry of Science and Innovation). C.E.M. is grateful for support by the Deutsche Forschungsgemeinschaft (DFG) within the Major Research Instrumentation scheme for a highly sensitive HPLC-MS instrument (QTRAP). The paid version of Biorender.com was utilized to prepare the illustrations, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M. Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., this work was funded by the spanish Ministerio de ciencia, innovación y universidades, Miciu/aei/10.13039/501100011033: Grants PiD2020-118127RB-i00 and PiD2023-147004OB-i00 (to s.V.), PiD2019-108691RB-i00 (to e.J.c.),PDc2021-121096 (to M.P. and c.s.), PiD2021-127693OB-i00 (to c.G.), PiD2022-141676NB-i00 (to F.F.);PiD2021-129034NB-i00 and PDc2022-133950-i00 (to s.O.); the Generalitat de catalunya (2021 sGR 00357 and 2021sGR 00487); the european Research council (eRc-2015-stG-679001-NetMoDezyme and eRc-2022-coG-101088032 tos.O.); the Xunta de Galicia (eD431c 2022/20); and the european Regional Development Fund (eRDF); Ministry ofscience and innovation, spain, with funds from the european union NextGenerationeu (PRtRc17.i1) and theautonomous community of Galicia within the framework of the 2023 Biotechnology Plan applied to health (to M.i.l.and J.B.). Partial support was provided by Nih-Niehs River award R35 es030443 and, Nih-Niehs superfund ProgramP42 es004699 to B.D.h. the content is solely the responsibility of the authors and does not necessarily represent theofficial views of the National institutes of health. M.R.c. was granted access to i24 beamline by the Diamond lightsource for (proposal number: MX32787). s.c. and a.l.t. received PhD fellowships from the universitat de Barcelona(aPiF grant) and the spanish Ministerio de educación, cultura y Deporte (FPu15/00889 grant), respectively. a.B.-M.,c.e., and M.s.-c. were supported by the Research Personnel training Program (FPi grants PRe2019-087468,PRe2022-104952, and PRe2020-096203, respectively) of the spanish Ministerio de ciencia, innovación y universidades(Miciu) and agencia estatal de investigación (aei). Q.Q. is funded by the King’s-china scholarship council PhDscholarship programme. F.F. received spanish MiciNN for a Ramón y cajal fellowship (RYc2020-029552-i). c.c.-t.received science Postdoctoral Fellowship from a schmidt Futures program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain [Dataset]

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., This work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades, MICIU/AEI/10.13039/501100011033: Grants PID2020-118127RB-I00 and PID2023-147004OB-I00 (to S.V.), PID2019-108691RB-I00 (to E.J.C.), PDC2021-121096 (to M.P. and C.S.), PID2021-127693OB-I00 (to C.G.), PID2022-141676NB-I00 (to F.F.); PID2021-129034NB-I00 and PDC2022-133950-I00 (to S.O.); the Generalitat de Catalunya (2021 SGR 00357 and 2021 SGR 00487); the European Research Council (ERC-2015-StG-679001-NetMoDEzyme and ERC-2022-CoG-101088032 to S.O.); the Xunta de Galicia (ED431C 2022/20); and the European Regional Development Fund (ERDF); Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health (to M.I.L. and J.B.). Partial support was provided by NIH-NIEHS River Award R35 ES030443 and, NIH-NIEHS Superfund Program P42 ES004699 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. M.R.C. was granted access to I24 beamline by the Diamond Light Source for (proposal number: MX32787). S.C. and A.L.T. received PhD fellowships from the Universitat de Barcelona (APIF grant) and the Spanish Ministerio de Educación, Cultura y Deporte (FPU15/00889 grant), respectively. A.B.-M., C.E., and M.S.-C. were supported by the Research Personnel Training Program (FPI grants PRE2019-087468, PRE2022-104952, and PRE2020-096203, respectively) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI). Q.Q. is funded by the King’s-China Scholarship Council PhD Scholarship programme. F.F. received Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). C.C.-T. received Science Postdoctoral Fellowship from a Schmidt Futures program., Peer reviewed